Skip to main content
U.S. Department of Health and Human Services
—
National Institutes of Health
Create Account
Login
Main menu
Discover
Share
Create
Learn
Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents
Autogenerated by
for
Max Schwiening
Created on Wed, 2020-10-14 09:49, last updated on Wed, 2020-10-14 09:49
I Printed This
Remix It
Vertical Tabs
General Information
This Model was autogenerated from the
"Quick Submit"
tool.
Model ID
3DPX-014937
Category
Proteins, Macromolecules and Viruses
Keyword(s)
GCN2, KINASE, INHIBITOR, Anti-tumor, TRANSFERASE-TRANSFERASE INHIBITOR complex
Protein Data Bank ID
6N3N
Experimental Method
X-RAY DIFFRACTION
Resolution
3.000
Model Details
Associated Species
unidentified baculovirus
Oligomeric Details
monomeric
R-Factor
0.2189
Scattering Type
x-ray
Attribution
PubMed ID
31 620 240
Digital Object Identifier (DOI)
10.1021/acsmedchemlett.9b00400
Citation Title
Identification of Novel, Potent, and Orally Available GCN2 Inhibitors with Type I Half Binding Mode.
Citation Year
2019
STL/VRML Files
PDB-6N3N-ribbon-secondary.wrl
PDB-6N3N-ribbon-rainbow.wrl
PDB-6N3N-ribbon-bychain.wrl
PDB-6N3N-ribbon.stl
PDB-6N3N-surf-bychain.wrl
PDB-6N3N-surf-hydropathy.wrl
PDB-6N3N-surf-coulombic.wrl
PDB-6N3N-surf.stl
PDB-6N3N.zip
X3D Files
PDB-6N3N-ribbon-secondary.x3d
PDB-6N3N-ribbon-rainbow.x3d
PDB-6N3N-ribbon-bychain.x3d
PDB-6N3N-ribbon.x3d
PDB-6N3N-surf-bychain.x3d
PDB-6N3N-surf-hydropathy.x3d
PDB-6N3N-surf-coulombic.x3d
PDB-6N3N-surf.x3d
Rating
Select rating
Give Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents 1/5
Give Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents 2/5
Give Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents 3/5
Give Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents 4/5
Give Identification of novel, potent and selective GCN2 inhibitors as first-in-class anti-tumor agents 5/5
Cancel rating
No votes yet
Licensing
Comments
0